Table 4 Adverse events occurring in ≥2% of patients in either age group
Adverse Event, n (%) | Elderly | Nonelderly | ||
|---|---|---|---|---|
1 mg | 2 mg | 2 mg | 3 mg | |
(n = 81) | (n = 83) | (n = 84) | (n = 77) | |
Dysgeusia | 15 (18.5) | 23 (27.7) | 36 (42.9) | 44 (57.1) |
Nasopharyngitis | 14 (17.3) | 18 (21.7) | 22 (26.2) | 14 (18.2) |
Headache | 4 (4.9) | 5 (6.0) | 3 (3.6) | 1 (1.3) |
Somnolence | 4 (4.9) | 2 (2.4) | 3 (3.6) | 6 (7.8) |
Upper respiratory tract infection | 4 (4.9) | 3 (3.6) | 2 (2.4) | 4 (5.2) |
Back pain | 4 (4.9) | 3 (3.6) | 2 (2.4) | 1 (1.3) |
Blood creatine phosphokinase increased | 4 (4.9) | 1 (1.2) | 3 (3.6) | 2 (2.6) |
Thirst | 3 (3.7) | 0 (0.0) | 2 (2.4) | 2 (2.6) |
Glucose urine present | 3 (3.7) | 2 (2.4) | 1 (1.2) | 1 (1.3) |
Dizziness | 1 (1.2) | 4 (4.8) | 0 (0.0) | 1 (1.3) |
Pharyngitis | 1 (1.2) | 2 (2.4) | 3 (3.6) | 1 (1.3) |